Ozempic, Wegovy and Mounjaro are linked with a small increase in gallbladder problems. The risk deserves a plan, not panic. Do not ignore persistent upper abdominal pain, and do not stop or restart treatment without clinical advice.
Someone loses weight successfully on Wegovy or Mounjaro, then develops pain under the right ribs. Was it the medicine, the weight loss, or both?
The honest answer is that the two effects are difficult to separate. Rapid or substantial weight loss is already a known setting for gallstones. GLP-1 medicines can produce that degree of loss, and trial evidence also shows a higher rate of gallbladder and bile-duct problems among people assigned to these medicines. Mounjaro, or tirzepatide, acts on both GIP and GLP-1 receptors, so its evidence is also considered separately below.
This should change how treatment is monitored. It should not turn a manageable risk into a reason to avoid effective care automatically.
What the evidence actually shows
He and colleagues pooled 76 randomised trials with 103,371 participants in JAMA Internal Medicine in 2022. People assigned to a GLP-1 medicine had a higher relative risk of gallbladder or biliary disease than people assigned to placebo or another treatment. The association was stronger in the 13 weight-loss trials than in trials for diabetes or other conditions.
That is a relative comparison across several medicines, doses and patient groups. It does not mean that most people develop gallstones, and it cannot predict one person's risk.
These figures come from different trial programmes, so they are not a head-to-head comparison. They should not be used to claim that one medicine is safer than the other.
A 2023 review led by Zeng included nine tirzepatide trials with 9,871 participants. It found an increase in the combined gallbladder or biliary outcome when tirzepatide was compared with placebo or basal insulin. The estimates for individual events such as gallstones or gallbladder inflammation were less certain. This is a useful warning against false precision.
What this means: both the treatment and the process of losing weight may contribute. The clinically useful question is not who to blame. It is whether symptoms are recognised early and whether the rate and quality of weight loss are being supervised.
Symptoms that need prompt assessment
Gallstones can cause no symptoms at all. When a stone blocks the normal flow of bile, symptoms may include:
- steady or severe pain in the upper right or upper middle abdomen
- pain that spreads to the back or right shoulder
- nausea or vomiting with the pain
- pain that repeatedly follows meals
Get urgent medical help
Seek urgent assessment for severe or persistent upper abdominal pain, especially with fever, repeated vomiting, yellow skin or eyes, dark urine, pale stools, faintness, or a marked decline in your condition. These symptoms can indicate gallbladder inflammation, a blocked bile duct, pancreatitis or another problem that cannot be diagnosed online.
Do not assume every stomach symptom is a routine Ozempic, Wegovy or Mounjaro side effect. Nausea, constipation and indigestion are common during dose escalation, but pain that is severe, localised, persistent or accompanied by warning signs needs a different response.
Also do not use a normal rise in pancreatic enzymes, or one symptom in isolation, to diagnose pancreatitis yourself. Current EU product information states that enzyme elevations alone do not predict acute pancreatitis. Clinical assessment is required.
Who needs a more careful discussion?
Before starting or increasing treatment, tell the clinician if you have had gallstones, gallbladder inflammation, bile-duct disease, pancreatitis or gallbladder surgery. Also mention any current upper abdominal symptoms.
A previous gallstone is not listed as an automatic contraindication in current EU product information for Wegovy or Mounjaro. It can still change the balance of risks, the pace of dose escalation and the threshold for investigation.
Risk is not controlled by dose alone. A sensible review also looks at:
- how quickly weight is changing
- whether food intake has become unnecessarily low
- hydration and the severity of vomiting or diarrhoea
- new abdominal symptoms
- the benefit the medicine is providing for weight, diabetes and related health risks
Routine ultrasound for every symptom-free patient is not established by the evidence cited here. Testing should follow the person's history, symptoms and clinical examination.
What not to do
- Do not crash diet to make the injection work faster. Faster is not automatically safer or easier to maintain.
- Do not raise, lower or skip doses to treat abdominal pain on your own. Significant pain needs assessment before a dosing decision.
- Do not restart automatically after an acute illness or procedure. The safe timing and dose depend on what happened and how long treatment was interrupted.
- Do not treat a serious symptom as the price of weight loss. A good result includes safety, strength and continuity, not only a lower number.
The maintenance view
Gallbladder risk exposes a common flaw in weight-loss care: the scale becomes the only outcome that matters.
Élan's aim is not the fastest possible drop. It is weight loss that can become stable, with enough nutrition, muscle-preserving activity, tolerable treatment and a plan for interruptions. That does not guarantee that gallstones will be prevented. It does reduce avoidable extremes and makes it more likely that warning symptoms are handled before treatment continuity breaks down.
If gallbladder disease is confirmed, the next plan depends on the diagnosis, treatment, recovery, the reason for using the medicine and the clinician's assessment. Some people may later continue or restart. Others may need a different approach. There is no safe universal restart rule.
Frequently asked questions
Do Ozempic, Wegovy and Mounjaro cause gallstones?
They are associated with a higher risk of gallbladder and biliary disease, but the cause is not simply the injection itself. Faster or larger weight loss also raises gallstone risk. The practical response is symptom awareness and individual risk review, not avoiding effective treatment automatically.
Should I stop a GLP-1 medicine if I get upper abdominal pain?
Do not diagnose or manage significant upper abdominal pain by yourself. Seek prompt medical assessment, especially if pain is severe, persistent, or occurs with fever, repeated vomiting, jaundice, dark urine or pale stools. The treating clinician should decide whether the medicine is paused or stopped.
Can I use Mounjaro or Wegovy if I have had gallstones before?
A history of gallstones is not listed as an automatic contraindication in current EU product information. It can change the risk discussion and monitoring plan, so disclose prior gallstones, gallbladder inflammation, pancreatitis and gallbladder surgery before treatment.
Can gallstones be prevented during GLP-1 weight loss?
No method removes the risk completely. Avoiding unnecessary crash dieting, using a clinically appropriate dose-escalation plan, maintaining adequate nutrition and reporting symptoms early are sensible parts of supervised care. Do not change a prescribed dose solely to prevent gallstones without medical advice.
The bottom line
Gallbladder problems affect only a small minority of people on these medicines, but they are a recognised risk during treatment with Wegovy, Ozempic and Mounjaro. The important distinction is between ordinary short-lived digestive effects and symptoms that need prompt medical assessment.
Safe weight management means watching the whole patient, planning for maintenance and responding early when the pattern changes.
Book an Estonia-based physician review. Élan Clinic can review GLP-1 tolerability, abdominal symptoms, weight-loss pace and the maintenance plan before you change treatment.
Sources
- He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine. 2022;182(5):513-519. Systematic review of 76 randomised trials; n=103,371. PMID: 35344001.
- Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide, pancreatitis and gallbladder or biliary disease, in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1214334. Systematic review of nine randomised trials; n=9,871. PMID: 37908750.
- European Medicines Agency. Wegovy: EU product information. Regulatory document, accessed July 16, 2026. Reports pooled phase 3a safety findings for acute gallstone disease and the EU precautions for acute pancreatitis.
- European Medicines Agency. Mounjaro: EU product information. Regulatory document, accessed July 16, 2026. Reports pooled phase 3 weight-management safety findings for gallbladder events and the EU precautions for acute pancreatitis.
This article is educational and does not replace individual diagnosis or treatment. Seek urgent medical care for severe or persistent abdominal pain or the warning symptoms listed above.